diffuse ecchymosis; thrombocytosis; splenomegaly/patients spleen is 22cm and so large/massive splenomegaly; thrombocytopenia; The patient is becoming anemic and leukopenic; causing painful breathing; Platelets were found to be @ 5000; it was affecting his breathing; eliciting pain with his breathing; The patient is becoming anemic and leukopenic; The patients platelets are so low; there is starting to be blood in the urine; bruising; constipated; abdominal pain; This is a spontaneous report from a contactable physician. A 26-year-old male patient received second dose bnt162b2 (BNT162B2, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 24Jun2021 as DOSE 2, SINGLE for covid-19 immunisation. Medical history included Occ smoker, non drinker. The patient's concomitant medications was not reported. Patient previously received first dose of bnt162b2(BNT162B2, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on unspecified date as DOSE 1, SINGLE for covid-19 immunisation. The patient experienced diffuse ecchymosis on 16Jul2021, thrombocytosis on 16Jul2021, splenomegaly/patients spleen is 22cm and so large/massive splenomegaly on 16Jul2021, the patient is becoming anaemic and leukopenic on 16Jul2021, causing painful breathing on 16Jul2021, thrombocytopenia on 16Jul2021, abdominal pain on 02Jul2021, platelets were found to be at 5000 on 16Jul2021, it was affecting his breathing on 16Jul2021, eliciting pain with his breathing on 16Jul2021, the patient was becoming anaemic and leukopenic on 16Jul2021, the patients platelets are so low on 16Jul2021, there was starting to be blood in the urine on 16Jul2021, constipated on 02Jul2021, bruising on 16Jul2021 patient was hospitalised for the events. The patient underwent lab tests and procedures which included abdominal x-ray: constipated on unspecified date, platelet count: 5000 on unspecified date, platelet count: 29k on unspecified date, platelet count: 6k on 16Jul2021, ultrasound doppler: negative on 16Jul2021. The outcome of the events ecchymosis, thrombocytosis, splenomegaly, leukopenia, painful respiration, thrombocytopenia, abdominal pain, platelet disorder, dyspnoea, pain, anaemia, platelet count decreased, blood urine, constipation, contusion was unknown.  Follow-up (18Jul2021): New information from a contactable physician included that: patient demographics and suspect drug information. limited information available over the call.  Follow-up (19Jul2021): New information received in response to the mail trail sent regarding the confirmation below mentioned query. The response included: no new medically significant information was received post authorisation safety reports medical information was not available and lab data for the second dose were reported.  Information about lot/batch number has been requested.; Sender's Comments: Based on the available information, there is a reasonable possibility of a causal relationship between the suspect vaccine BNT162B2 (COMIRNATY) and reported events ecchymosis, Thrombocytopenia, Leucopenia, Splenomegaly and thrombocytosis cannot be fully assessed/excluded. The case will be reassessed if additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.